Quoin Pharmaceuticals, Ltd.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

QNRX$3.91+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 6. Exhibits

The following exhibits are included in this Form 10-Q or incorporated herein by reference:

ExhibitNo.		Exhibit Description
3.1		Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd. (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K filed with the SEC on March 13, 2025).
3.2		Amendment to Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on August 21, 2025 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the Commission on August 21, 2025).
4.1		Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed with the Commission on October 15, 2025).
4.2		Form of Series H Warrant (incorporated by reference to Exhibit 4.2 to Form 8-K filed with the Commission on October 15, 2025).
4.3		Form of Series I Warrant (incorporated by reference to Exhibit 4.3 to Form 8-K filed with the Commission on October 15, 2025).
4.4		Form of Series J Warrant (incorporated by reference to Exhibit 4.4 to Form 8-K filed with the Commission on October 15, 2025).
4.5		Form of Series K Warrant (incorporated by reference to Exhibit 4.5 to Form 8-K filed with the Commission on October 15, 2025).
10.1#†		Settlement Agreement, effective August 15, 2025, by and between Quoin Pharmaceuticals, Inc., and Gordon Dunn (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the Commission on August 27, 2025).
10.2#		Service Agreement, dated August 18. 2025, by and between Quoin Therapeutics (Ireland) Ltd. and Sally Lawlor (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the Commission on August 21, 2025).
10.3#		2025 Equity Incentive Plan of Quoin Pharmaceuticals, Ltd. (incorporated by reference to Exhibit 4.4 to Registration Statement on Form S-8 filed with the Commission on August 27, 2025).
10.4		Form of Securities Purchase Agreement, dated October 10, 2025 (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the Commission on October 15, 2025).
10.5		Form of Registration Rights Agreement, dated October 10, 2025 (incorporated by reference to Exhibit 10.2 to Form 8-K filed with the Commission on October 15, 2025).
31.1*		Certification of Chief Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934
31.2*		Certification of Chief Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934
32.1**		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350
32.2**		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350
101*		Information formatted in Inline XBRL (Extensible Business Reporting Language) : (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Shareholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
104*		Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101)

*Filed herewith

**Furnished herewith

#Indicates management contract or compensatory plan or arrangement

†Exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit to the SEC upon request.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.